calcium chloride injection
cardinal health - calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb) - calcium chloride 100 mg in 1 ml
calcium gluconate injection solution
remedyrepack inc. - calcium gluconate (unii: sqe6vb453k) (calcium cation - unii:2m83c4r6zb) - calcium gluconate 94 mg in 1 ml
calcium gluconate injection solution
general injectables & vaccines, inc. - calcium gluconate (unii: sqe6vb453k) (calcium cation - unii:2m83c4r6zb) - calcium gluconate 94 mg in 1 ml
calcium gluconate injection solution
app pharmaceuticals, llc - calcium gluconate (unii: sqe6vb453k) (calcium cation - unii:2m83c4r6zb) - calcium gluconate 94 mg in 1 ml
calcium gluconate injection solution
fresenius kabi usa, llc - calcium gluconate (unii: sqe6vb453k) (calcium cation - unii:2m83c4r6zb) - calcium gluconate 94 mg in 1 ml
calcium acetate tablet
camber pharmaceuticals, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate tablets contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. a c
plus pharma calcium antacid- calcium carbonate tablet, chewable
gemini pharmaceuticals, inc. dba plus pharma - calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb) - calcium carbonate 500 mg - antacid for the relief of - heartburn - sour stomach - acid indigestion - upset stomach associated with these symptoms
healthmart calcium antacid- calcium carbonate tablet, chewable
strategic sourcing services llc - calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb) - calcium cation 750 mg - antacid relieves: - acid indigestion - heartburn
calcium acetate capsule
remedyrepack inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and d
calcium acetate capsule
lupin pharmaceuticals, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unk